Indivior, Braeburn, And Two Very Well-Timed Anti-Addiction Applications
Executive Summary
US FDA advisory committee had dosing and dispensing concerns about both buprenorphine injectable products, but each ended up with a strong vote in favor, clearly benefiting from public health attention to opioid addiction and the call for broader access to treatment.
You may also be interested in...
Blocked By Sublocade: Braeburn Sues To Get Brixadi Buprenorphine Formulation Onto Market
Lawsuit against US FDA challenges scope of three-year exclusivity awarded to Indivior’s Sublocade, the first monthly depot formulation of buprenorphine for treating opioid use disorder.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.